## BMRN: BioMarin Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.8% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($49.20)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Hudson Bay Capital Management LP Sells 60,425 Shares of BioMarin Pharmaceutical Inc. $BMRN**
- Source: MarketBeat | 20251214T130855 | Neutral | Relevance: 100%
- Hudson Bay Capital Management LP has reduced its stake in BioMarin Pharmaceutical Inc. by selling 60,425 shares, leaving them with 526,420 shares valued at approximately $28.94 million. BioMarin missed quarterly EPS and revenue estimates but provided optimistic FY2025 guidance. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $88.61.

**2. BioMarin Pharmaceutical Inc. $BMRN Holdings Lowered by Hudson Bay Capital Management LP**
- Source: MarketBeat | 20251214T120855 | Neutral | Relevance: 100%
- Hudson Bay Capital Management LP reduced its stake in BioMarin Pharmaceutical Inc. ($BMRN) by 10.3% in Q2, while several other major institutional investors, including Dodge & Cox and Viking Global, significantly increased their holdings. Analysts maintain a "Moderate Buy" consensus despite the company missing recent quarterly EPS expectations. Institutional investors now own approximately 98.71% of BioMarin's stock.

**3. Bellevue Group AG Lowers Stake in BioMarin Pharmaceutical Inc. $BMRN**
- Source: MarketBeat | 20251213T090943 | Neutral | Relevance: 100%
- Bellevue Group AG significantly reduced its stake in BioMarin Pharmaceutical Inc. by 58.9% in Q2, selling 216,928 shares, although other institutional investors like Dodge & Cox, Viking Global, AQR, Geode, and Norges Bank increased their positions. Despite BioMarin missing Q2 EPS and revenue estimates, institutional ownership remains high at 98.71%, and analysts maintain a "Moderate Buy" consensus with an $88.61 target, anticipating a strong FY2025 EPS guidance.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | Leerink Partner | $60 | $82 | -27% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | Leerink Partner | down | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 11.5% (-8.1%)
- Vanguard Group Inc: 9.7% (-2.2%)
- Primecap Management : 7.9% (-3.4%)
- Dodge & Cox Inc.: 7.6% (-2.8%)
- State Street Corpora: 4.6% (-0.9%)

### Key Risks

1. Long-term trend broken: trading 10.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 9.9x attractive for 47% earnings growth. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (4.8x), low leverage (D/E 0.26). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 0.30 |
| 52W Range | $50.76 - $73.51 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 9.9 |
| Current P/E | 14.6 |
| YoY Growth | 47.1% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -2.2% to -0.8% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.8pp (needs >3.0% for momentum thesis). Below SMA200 (0.89x), long-term trend not supportive. RSI neutral at 40. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.81% (CS: 20) | Neutral |
| RSI_14 | 40.4 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 0.964x | Below |
| vs SMA50 | 0.971x | Below |
| vs SMA200 | 0.894x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $52.12
- **Stop Loss:** $49.20 (5.6% risk)
- **Target:** $55.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 410
- **Position Value:** $21,369.20
- **Portfolio %:** 21.37%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-19 (Est: $0.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.31 | $0.12 | -61.1% |
| 2025Q2 | $1.01 | $1.44 | +42.3% |
| 2025Q1 | $0.95 | $1.13 | +18.6% |
| 2024Q4 | $0.74 | $0.92 | +24.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*